Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization
Test results in three and half hours
Roche announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the cobas® SARS-CoV-2 Test. It is intended for the qualitative detection of SARS-CoV-2, the virus that causes Covid-19 disease, in nasopharyngeal and oropharyngeal swab samples from patients who meet COVID-19 clinical and/or epidemiological criteria for testing. Hospitals and reference laboratories can run the test on Roche’s fully automated cobas® 6800 and cobas® 8800 Systems, which are widely available in the U.S. and around the world.
The CE-IVD test is also available in markets accepting the CE mark for patients with signs and symptoms of COVID-19 disease and living in affected areas where the SARS-CoV-2 virus is known to be present.
"Providing quality, high-volume testing capabilities will allow us to respond effectively to what the World Health Organization has characterized as a pandemic. It is important to quickly and reliably detect whether a patient is infected with SARS-CoV-2,” said Thomas Schinecker, CEO of Roche Diagnostics. “Over the last weeks, our emergency response teams have been working hard to bring this test to the patients. CE-mark certification and the FDA’s granting of EUA supports our commitment to give more patients access to reliable diagnostics which are crucial to combat this serious disease.”
The widely available Roche’s cobas 6800/8800 Systems, which are used to perform the cobas SARS-CoV-2 Test, provide test results in three and half hours and offer improved operating efficiency, flexibility, and fastest time-to-results with the highest throughput providing up to 96 results in about three hours and a total of 1,440 results for the cobas 6800 System and 4,128 results for the cobas 8800 System in 24 hours. The test can be run simultaneously with other assays provided by Roche for use on the cobas 6800/8800 Systems.
Upon authorisation Roche will have millions of tests a month available for use on the cobas 6800 and 8800 systems. Roche is committed to delivering as many tests as possible and is going to the limits of our production capacity.
Symbolic image
geralt, pixabay.com, CC0
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Eurofins expands food and feed testing business in the US
Parkinson's disease - New test procedure enables early detection in patients at risk - Up to seven years before the onset of typical motor symptoms
Ultrafast snapshots of relaxing electrons in solids
CLC bio achieves massive growth in 2009 and closes year with 7-figure deal
Researchers 3D print components for a portable mass spectrometer - Lightweight and inexpensive, miniaturized mass filters are a key step toward portable mass spectrometers that could identify unknown chemicals in remote settings
New polymer mixture creates ultra-sensitive heat sensor - Polymer gels with tunable ionic Seebeck coefficient for ultra-sensitive printed thermopiles
First look at how our cells can 'swallow up and quarantine' Zika
Prion fingerprints detected with glowing molecule
Monitoring the corrosion of bioresorbable magnesium - Better prediction of degradation rate of magnesium implants
Unlike rubber bands, molecular bonds may not break faster when pulled
Machine learning reveals the mysteries of thin films at atomic scale - High-accuracy atomistic modeling of amorphous materials
